On October 7, INNOCARE fell 5.01% in regular trading, trading at 13.27 HKD/share, with turnover of 3.8525 million HKD.

On the news front, the broader biotechnology sector suffered a sharp pullback, with the Hang Seng Biotech Index down 3.15% and the Hang Seng Healthcare Index down 2.73%, dampening sentiment toward individual names in the sector.

Background context shows the company signed a research collaboration and license agreement with Eli Lilly in late September worth up to 3.35 billion USD, but the positive catalyst has largely been priced in by the recent rally. Meanwhile, multiple shareholders have disclosed reductions in their holdings, raising profit-taking pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)